Assays for membrane tyrosine kinase receptors: Methods for high-throughput screening and utility for diagnostics

Expert Review of Molecular Diagnostics

Volumn 5, Issue 4, 2005, Pages 561-571

  Minor, Lisa K ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cell based assay; High throughput screen; Membrane tyrosine kinase receptor

Indexed keywords

ADENOSINE TRIPHOSPHATE; BECAPLERMIN; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; INSULIN RECEPTOR; PANITUMUMAB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; SUNITINIB; TYROSINE KINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

DEVICE; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE POLARIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; IMAGE ANALYSIS; LUMINESCENCE; PROTEIN PHOSPHORYLATION; RADIOACTIVITY; RECEPTOR BINDING; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DRUG DELIVERY SYSTEMS; FLUORESCENCE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PROTEIN TRANSPORT; RADIOISOTOPES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 22044441747     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.5.4.561     Document Type: Review

References (47)

1. Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 411(6835), 355-365 (2001). Excellent review of tyrosine kinases.
2. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103(2), 211-225 (2000).
3. Levitzki A. Protein tyrosine kinase inhibitors as therapeutic agents. Topics in Current Chemistry. 211 (Bioorganic Chemistry of Biological Signal Transduction), 1-15 (2001).
4. Robinson DR, Wu Y-M, Lin S-F. The protein tyrosine kinase family of the human genome. Oncogene 19(49), 5548-5557 (2000).
5. Manning G, Whyte DB, Martinez R et al. The protein kinase complement of the human genome. Science 298(5600), 1912-1934 (2002).
6. Augustin HG, Breier G. Angiogenesis: molecular mechanisms and functional interactions - 2nd Kloster Seeon Meeting of the German Priority Research Grant "Angiogenesis". Thromb. Haemost. 89(1), 190-197 (2003).
7. Siemeister G, Martiny-Baron G, Marme D. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Cancer Metastasis Rev. 17(2), 241-248 (1998).
8. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358(9277), 221-229 (2001).
9. DeFronzo RA. Pathogenesis of Type 2 diabetes mellitus. Med. Clin. North Am. 88(4), 787-835 (2004). Excellent review of Type 2 diabetes.
10. No authors listed. A new way to take insulin. The daily needle stick may soon be a thing of the past as inhaled insulin takes hold. Health News 10(9), 10 (2004). Insulin as an inhaled treatment.
11. Quattrin T. Inhaled insulin: recent advances in the therapy of Type 1 and 2 diabetes. Expert Opin. Pharmacother. 5(12), 2597-2604 (2004).
12. Einhorn D. Advances in diabetes for the millennium: insulin treatment and glucose monitoring. MedGenMed. 6(2), 8 (2004).
13. Liu K, Xu L, Wood HB et al. Small-molecule insulin mimetics with potential utilities as antidiabetic and anti-obesity therapies. Abstracts of Papers, 225th ACS National Meeting, New Orleans, LA, United States, March 23-27, 2003. MEDI-187 (2003). Small-molecule insulin mimetics: demonstrates that a cell-based approach can identify mimetics of membrane tyrosine kinase receptors.
14. Barker AJ, Gibson KH, Grundy W et al. Studies leading to the identification of zd1839 (Iressa): an orally-active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 11(14), 1911-1914 (2001). Identification of gefitinib.
15. Higgins B, Kolinsky K, Smith M et al. Antitumor activity of erlotinib (osi-774, tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 15(5), 503-512 (2004).
16. Kubo K, Shimizu T, Ohyama S-I et al. A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation. Bioorg. Med. Chem. Lett. 7(23), 2935-2940 (1997).
17. McCarty MF, Wey J, Stoeltzing O et al. Zd6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol. Cell. Ther. 3(9), 1041-1048 (2004).
18. Pandey A, Volkots DL, Seroogy JM et al. Identification of orally-active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J. Med. Chem. 45(17), 3772-3793 (2002).
19. Solca FF, Baum A, Langkopf E et al. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. J. Pharmacol. Exp. Ther. 311(2), 502-509 (2004).
20. Parast CV, Mroczkowski B, Pinko C et al. Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 tk), a key enzyme in angiogenesis. Biochemistry 37(47), 16788-16801 (1998).
21. Zaman GJR, Vink PMF, van den Doelen AA et al. Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor β-receptor (β-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases. Biochem. Pharmacol. 57(1), 57-64 (1999).
22. Brown BA, Cain M, Broadbent J et al. Flashplate technology. High Throughput Screen. 317-328 (1997). Discussion of FlashPlate® technology.
23. Nakayama GR, Nova MP, Parandoosh Z. A scintillating microplate assay for the assessment of protein kinase activity. J. Biomol. Screen. 3(1), 43-48 (1998). SPA® protein kinase assay.
24. Park Y-W, Cummings RT, Wu L et al. Homogeneous proximity tyrosine kinase assays: scintillation proximity assay versus homogeneous time-resolved fluorescence. Anal. Biochem. 269(1), 94-104 (1999).
25. Parker GJ, Law TL, Lenoch FJ et al. Development of high-throughput screening assays using fluorescence polarization: nuclear receptor-ligand- binding and kinase/phosphatase assays. J. Biomol. Screen. 5(2), 77-88 (2000).
26. Logianzo F, Hardy C. A sensitive, time-resolved fluorometric assay for detection of inhibitors of phosphotyrosine kinases. Am. Biotechnol. Lab. 16(13), 26-28 (1998).
27. Warner G, Illy C, Pedro L et al. Alphascreen kinase HTS platforms. Curr. Med. Chem. 11(6), 721-730 (2004). AlphaScreen™ kinase platforms.
28. Eglen RM. Enzyme fragment complementation: a flexible high-throughput screening assay technology. Assay Drug Dev. Technol. 1(1-1), 97-104 (2002). Good description of enzyme fragment complementation.
29. Beasley J, McCoy PM, Walker TL, Dunn DA. Miniaturized, ultra-high-throughput screening of tyrosine kinases using homogeneous, competitive fluorescence immunoassays. Assay Drug Dev. Technol. 2(2), 141-151 (2004).
30. Koresawa M, Okabe T. High-throughput screening with quantitation of ATP consumption: a universal non-radioisotope, homogeneous assay for protein kinase. Assay Drug Dev. Technol. 2(2), 153-160 (2004). ATP-consumption kinase assays: a potential breakthrough technology.
31. Carpenter JW, Laethem C, Hubbard FR et al. Configuring radioligand receptor binding assays for HTS using scintillation proximity assay technology. Methods Mol. Biol. 190, 31-49 (2002).
32. Mahoney CW. High-throughput nonradioisotopic determination of binding of platelet-derived growth factor to platelet-derived growth factor receptor β-extracellular domain using biotinylated ligand with enzyme-linked immunosorbent assay. Anal. Biochem. 276(1), 106-108 (1999).
33. Wilson J, Rossi CP, Carboni S et al. A homogeneous 384-well high-throughput binding assay for a TNF receptor using Alphascreen technology. J. Biomol. Screen. 8(5), 522-532 (2003).
34. Horgan AM, Stork PJS. Examining the mechanism of Erk nuclear translocation using green fluorescent protein. Exp. Cell Res. 285(2), 208-220 (2003). Cell-based assay studying transcription factor movement into the nucleus.
35. Ding GJF, Fischer PA, Boltz RC et al. Characterization and quantitation of NF-κB nuclear translocation induced by interleukin-1 and tumor necrosis factor-α. Development and use of a high capacity fluorescence cytometric system. J. Biol. Chem. 273(44), 28897-28905 (1998).
36. King IC, Feng M, Catino JJ. High throughput assay for inhibitors of the epidermal growth factor receptor-associated tyrosine kinase. Life Sci. 53(19), 1465-1472 (1993). First plate-based assay describing receptor phosphorylation quantification.
37. Sadick MD, Intintoli A, Quarmby V et al. Kinase receptor activation (KIRA): a rapid and accurate alternative to end point bioassays. J. Pharm. Biomed. Anal. 19(6), 883-891 (1999).
38. Angeles TS, Lippy JS, Yang SX. Quantitative, high-throughput cell-based assays for inhibitors of trkA receptor. Anal. Biochem. 278(2), 93-98 (2000).
39. Biazzo-Ashnault DE, Park Y-W, Cummings RT et al. Detection of insulin receptor tyrosine kinase activity using time-resolved fluorescence energy transfer technology. Anal. Biochem. 291(1), 155-158 (2001).
40. Malik SN, Bedolla RG, Hidalgo M et al. Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples. Methods Mol. Med. 85, 135-140 (2003). Clinical determination of receptor phosphorylation.
41. Eppenberger-Castori S, Kueng W, Benz C et al. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J. Clin. Oncol. 19(3), 645-656 (2001).
42. Thor AD, Liu S, Moore D II et al. Activation (tyrosine phosphorylation) of erbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J. Clin. Oncol. 18(18), 3230-3239 (2000).
43. Abrams T, Lee LB, Murray LJ, Pryer NK, Cherrington JM. Su11248 inhibits kit and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2, 471-478 (2003).
44. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337 (2003). Important paper describing the use of receptor phosphorylation to determine the pharmacokinetic/pharmacodynamic properties of a receptor tyrosine kinase inhibitor.
45. Van Den Bossche B, Van de Wiele C. Receptor imaging in oncology by means of nuclear medicine: current status. J. Clin. Oncol. 22(17), 3593-3607 (2004). Current status of receptor imaging in oncology.
46. Mandell J. Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am. J. Pathol. 163(5), 1687-1698 (2003).
47. Minor LK, Westover L, Kong Y et al. Validation of a cell-based screen for insulin receptor modulators by quantification of insulin receptor phosphorylation. J. Biomol. Screen. 8(4), 439-446 (2003).